Molecular and Cellular Biology (MCB) Core
- Funded by National Institutes of Health (NIH)
- Total publications:0 publications
Grant number: 2P20GM130448-06
Grant search
Key facts
Disease
Disease XStart & end year
20202031Known Financial Commitments (USD)
$248,927Funder
National Institutes of Health (NIH)Principal Investigator
PROFESSOR WAITHAKA MWANGIResearch Location
United States of AmericaLead Research Institution
KANSAS STATE UNIVERSITYResearch Priority Alignment
N/A
Research Category
13Research Subcategory
N/ASpecial Interest Tags
N/AStudy Type
Not applicableClinical Trial Details
N/ABroad Policy Alignment
PendingAge Group
UnspecifiedVulnerable Population
UnspecifiedOccupations of Interest
Unspecified
Abstract
Project Summary- MOLECULAR AND CELLULAR BIOLOGY (MCB) CORE The Molecular and Cellular Biology (MCB) Core at Kansas State University (KSU) is central to the Center on Emerging and Zoonotic Infectious Diseases (CEZID), aiming to strengthen CEZID research through advanced technologies and technical expertise. The Core's mission is to support CEZID-affiliated investigators by enabling high-quality, impactful research, thereby improving their competitiveness for NIH funding. Recent facility enhancements include relocation to the Biomedical Core Facilities (BCF), doubling its operational space and acquiring state-of-the-art new instruments. The Core offers essential services using cutting edge technologies such flow cytometry, next-generation sequencing (NGS), single-cell gene expression profiling, CRISPR genome editing, and spatial transcriptomics. In Phase 1, the MCB Core delivered critical support by processing over 3,200 Illumina sequencing samples and providing more than 870 hours of confocal microscopy and flow cytometry usage. It played a crucial role in 57 peer-reviewed publications and supported multiple successful grant applications. Despite challenges from the COVID-19 pandemic and facility relocations, the Core successfully implemented advanced technologies like single-cell RNA sequencing and spatial transcriptomics. These achievements lay a strong foundation for expanded capabilities and user engagement in Phase 2. In Phase 2 of CEZID, the MCB core will work to fulfill three specific aims: (1) Empower CEZID investigators to attain NIH awards; (2) Expand high-throughput sequencing capabilities; and (3) Advance transcriptomics research, including single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics. Leadership by expert scientists ensures robust technical support and mentoring. Infrastructure investments include high-end platforms like the 10X Genomics Chromium and advanced imaging systems. In Phase 2, new hires and equipment upgrades, such as the Cytek Aurora flow cytometer and Illumina NextSeq2000, will enhance the Core's capabilities. The MCB Core plays a vital role in mentoring researchers and training students, fostering interdisciplinary collaboration. It partners with the Animal Model and Pathology (AMP) Core and provides comprehensive training in experimental design, equipment use, and data analysis. Sustainability plans integrate institutional support, service fees, and grant funding to maintain operations. The Core is key to CEZID's broader impact, extending services to external partners and contributing to pandemic preparedness through innovative research infrastructure.